Sun Pharmaceutical Industries Limited has notified its shareholders regarding a special window established by the Securities and Exchange Board of India (SEBI) for the transfer of physical shares. This initiative aims to facilitate ease of investing and secure the rights of investors in securities purchased before the dematerialization mandate.

Special Window Details

The special window is open for a period of one year, effective from 05 February 2026 to 04 February 2027. It covers physical shares that were sold or purchased prior to 01 April 2019. Additionally, this window accommodates transfer requests that were submitted earlier but were rejected, returned, or not processed due to deficiencies in documents or processes.

Transfer Conditions

During this period, any securities transferred under this scheme will be mandatorily credited to the transferee only in demat mode. These securities will be subject to a lock-in period of one year from the date of registration of transfer. Consequently, the shares cannot be transferred, lien-marked, or pledged during the said lock-in period.

Submission Requirements

Investors wishing to utilize this facility must submit the requisite documents to the company's Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited. The required documents include original share certificates, the transfer deed executed prior to 01 April 2019, proof of purchase by the transferee, KYC documents of the transferee, and a latest Client Master List (CML) of the transferee's demat account, not older than two months.

Contact Information

Shareholders can send their documents to MUFG Intime India Private Limited, located at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400083. For queries, investors can contact the RTA via email at investor.helpdesk@im.mpsg.mufg.com or call +91 810 811 6767. The company has also published advertisements in newspapers and will be sharing information on social media platforms to raise awareness about this facility.

Sun Pharmaceutical Industries Limited has informed stock exchanges that it received requests on 14 May 2026 from three members of its Promoter Group seeking reclassification of their shareholder category from 'Promoter Group' to 'Public' under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in compliance with Regulation 30 and Regulation 31A of the Listing Regulations.

Shareholders Seeking Reclassification

The three individuals who have submitted reclassification requests are Mr. Sudhir Vrundavandas Valia, Mrs. Raksha Sudhir Valia, and Mrs. Krishna Vrundavandas Valia. The table below details the shareholding of each applicant as disclosed in the intimation:

Mrs. Krishna Vrundavandas Valia's shareholding details were not disclosed in the intimation.

Regulatory Process and Next Steps

The company has stated that the reclassification requests will be examined in accordance with the applicable provisions of the Listing Regulations. Upon completion of the examination, the requests will be placed before the Board of Directors for its consideration. Subject to Board approval and completion of the prescribed regulatory process, Sun Pharmaceutical will take necessary steps, including submission of the application to the stock exchanges.

The intimation was signed by Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983), and was digitally authenticated on 14 May 2026.